Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Morus alba ethanolic extract is a botanical research compound derived from the white mulberry plant (*Morus alba L.*) using ethanol as a solvent. It contains a diverse array of bioactive phytochemicals, including flavonoids such as quercetin, kaempferol, and isorhamnetin, as well as phenolic acids like chlorogenic acid. The extract has demonstrated therapeutic potential in preclinical models for various conditions, including epilepsy (via modulation of GABA-A and 5-HT3A receptors), obesity (through melanin-concentrating hormone-1 receptor antagonism), and diabetes (via AMPK/mTOR-mediated autophagy and pancreatic islet protection). It also exhibits neuroprotective, antioxidant, and antibacterial properties. As a complex botanical extract, its pharmacological profile is attributed to the synergistic effects of its multiple constituents rather than a single active ingredient.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on morus alba ethanolic extract.